Basics |
Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
|
IPO Date: |
April 28, 2017 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$964M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.46 | 2.63%
|
Avg Daily Range (30 D): |
$0.26 | 2.01%
|
Avg Daily Range (90 D): |
$0.28 | 2.29%
|
Institutional Daily Volume |
Avg Daily Volume: |
.43M |
Avg Daily Volume (30 D): |
.32M |
Avg Daily Volume (90 D): |
.43M |
Trade Size |
Avg Trade Size (Sh.): |
104 |
Avg Trade Size (Sh.) (30 D): |
60 |
Avg Trade Size (Sh.) (90 D): |
62 |
Institutional Trades |
Total Inst.Trades: |
1,475 |
Avg Inst. Trade: |
$1.73M |
Avg Inst. Trade (30 D): |
$1.49M |
Avg Inst. Trade (90 D): |
$1.29M |
Avg Inst. Trade Volume: |
.12M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.34M |
Avg Closing Trade (30 D): |
$1.5M |
Avg Closing Trade (90 D): |
$1.26M |
Avg Closing Volume: |
106.21K |
|
|
Financials |
|
TTM |
Q1 2025 |
Q4 2024 |
Basic EPS
|
$-1.5
|
$-.3
|
$-.32
|
Diluted EPS
|
$-1.5
|
$-.3
|
$-.32
|
Revenue
|
$ 93.38M
|
$ 27.11M
|
$ 31.03M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -113.68M
|
$ -22.64M
|
$ -23.51M
|
Operating Income / Loss
|
$ -124.92M
|
$ -25.61M
|
$ -22.22M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -38.61M
|
$ 10.1M
|
$ -56.25M
|
PE Ratio
|
|
|
|
|
|
|